Samanen J, Cash T, Narindray D, Brandeis E, Yellin T, Regoli D
Smith Kline and French Laboratories, Peptide Chemistry Department, King of Prussia, Pennsylvania 19406-0939.
J Med Chem. 1989 Jun;32(6):1366-70. doi: 10.1021/jm00126a037.
A number of [Sar1,(pX)Phe4]-ANG II and [Sar1,(pX)Phe4,Ile8]-ANG II analogues were prepared. A good correlation between pX structure in [Sar1,(pX)Phe4]-ANG II and antagonist activity could not be found. However, the data suggest a general trend: Position 4 para substituents that are hydrophilic and capable of donating a hydrogen atom in a hydrogen bond promote agonist activity, while para substituents that are hydrophobic and incapable of donating a hydrogen atom promote antagonist activity. These properties were found to be optimal in the p-chloro substituent. The resulting analogue [Sar1,(pCl)Phe4]-ANG II is a potent ANG II antagonist in vivo. The pX substituents that promote antagonist activity in the [Sar1,(pX)Phe4]-ANG II series were unfavorable in [Sar1,(pX)Phe4,Ile8]-ANG II analogues. ANG II analogues that are antagonists by virtue of an alteration in position 8 require a position 4 agonist side chain. Concurrent modifications of positions 4 and 8 do not give rise to potent antagonists with reduced partial agonist activity.
制备了多种[Sar1,(pX)Phe4]-ANG II和[Sar1,(pX)Phe4,Ile8]-ANG II类似物。未发现[Sar1,(pX)Phe4]-ANG II中pX结构与拮抗剂活性之间存在良好的相关性。然而,数据表明了一个总体趋势:[Sar1,(pX)Phe4]-ANG II中4位对位取代基若是亲水性的且能够在氢键中提供氢原子,则促进激动剂活性;若是疏水性的且不能提供氢原子,则促进拮抗剂活性。发现这些性质在对氯取代基中是最佳的。所得类似物[Sar1,(pCl)Phe4]-ANG II在体内是一种有效的ANG II拮抗剂。在[Sar1,(pX)Phe4]-ANG II系列中促进拮抗剂活性的pX取代基在[Sar1,(pX)Phe4,Ile8]-ANG II类似物中是不利的。由于8位改变而成为拮抗剂的ANG II类似物需要4位有激动剂侧链。4位和8位的同时修饰不会产生具有降低的部分激动剂活性的强效拮抗剂。